Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Clin Cancer Res
    May 2026
  1. LEE EJ, Ko JA, Kim MJ, Cho JS, et al
    JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.
    Clin Cancer Res. 2026;32:1835-1845.
    >> Share

    April 2026
  2. HASHMI A, Linford J, Chauhan PS, Parikh K, et al
    Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy.
    Clin Cancer Res. 2026 Apr 30. doi: 10.1158/1078-0432.CCR-25-4983.
    >> Share

  3. LEE JB, Kim DK, Lee SH, Kim KH, et al
    A Phase 2 Study of Stereotactic Ablative Radiotherapy Plus Atezolizumab Plus Tiragolumab in Treatment-naive Patients with Advanced Non-small Cell Lung Cancer.
    Clin Cancer Res. 2026 Apr 20. doi: 10.1158/1078-0432.CCR-25-4990.
    >> Share

  4. THURSBY SJ, Jin Z, Blum J, Gurau A, et al
    Epigenetic Instability-Based Metrics in Cell-Free DNA for Early Cancer Detection.
    Clin Cancer Res. 2026;32:1528-1539.
    >> Share

  5. GRAY JE, Neal JW, Patel JD, Liu SV, et al
    First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.
    Clin Cancer Res. 2026 Apr 10. doi: 10.1158/1078-0432.CCR-25-4485.
    >> Share

    March 2026
  6. HUANG B, Zhao J, Zhu J, Wang X, et al
    Low-dose intestinal irradiation enhances the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer.
    Clin Cancer Res. 2026 Mar 18. doi: 10.1158/1078-0432.CCR-25-4153.
    >> Share

  7. SIERRA-RODERO B, Gil-Gonzalez A, Molina-Alejandre M, Nadal E, et al
    Decoding B Cell Signatures of Complete Pathological Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Mar 10. doi: 10.1158/1078-0432.CCR-25-3315.
    >> Share

  8. GRAY JE, Laktionov K, Kim SW, Kato T, et al
    Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Mar 9. doi: 10.1158/1078-0432.CCR-25-3431.
    >> Share

  9. YU HA, Tang KH, Markovets AA, Hartmaier R, et al
    Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.
    Clin Cancer Res. 2026 Mar 6. doi: 10.1158/1078-0432.CCR-25-4540.
    >> Share

  10. WU X, Sun K, Zhang J, Hou S, et al
    Locus-specific human endogenous retrovirus ERVK18 expression indicates an inflamed microenvironment and favorable immunotherapy outcome in small cell lung cancer.
    Clin Cancer Res. 2026 Mar 5. doi: 10.1158/1078-0432.CCR-25-3302.
    >> Share

  11. IRAJIZAD E, Fahrmann JF, Wu R, Rudsari H, et al
    Association of blood levels of forever plastics with lung cancer mortality among ever smokers in the Prostate Lung Colorectal and Ovarian (PLCO) cohort study.
    Clin Cancer Res. 2026 Mar 4. doi: 10.1158/1078-0432.CCR-25-3846.
    >> Share

    February 2026
  12. CHEN M, Bulat I, Maglakelidze M, Li N, et al
    Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.
    Clin Cancer Res. 2026 Feb 11. doi: 10.1158/1078-0432.CCR-25-2173.
    >> Share

    January 2026
  13. LIU Y, Nashed J, Barone AK, Yuan M, et al
    FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-2287.
    >> Share

  14. PFEIL AJ, Zhang T, Cheng R, Mattar MS, et al
    RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.
    Clin Cancer Res. 2026 Jan 16. doi: 10.1158/1078-0432.CCR-25-2734.
    >> Share

  15. PROVENCIO M, Serna-Blasco R, Nadal E, Gonzalez Larriba JL, et al
    Minimal Residual Disease Enhances Prognostic Stratification Beyond Pathological Response in Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jan 15. doi: 10.1158/1078-0432.CCR-25-2958.
    >> Share

    December 2025
  16. JOHN F, Ruge L, Verheyen M, Scharpenseel H, et al
    Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS G12V mutations.
    Clin Cancer Res. 2025 Dec 19. doi: 10.1158/1078-0432.CCR-25-2581.
    >> Share

  17. ARMSTRONG AJ, Dietz H, Balli D, Geese WJ, et al
    LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.
    Clin Cancer Res. 2025;31:5198-5210.
    >> Share

    November 2025
  18. BALASUBRAMANIAN A, Marceaux C, Kanwal S, Tarasova I, et al
    Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.
    Clin Cancer Res. 2025;31:4644-4654.
    >> Share

  19. PECCI F, Li H, Di Federico A, Wu J, et al
    First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy +/- Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.
    Clin Cancer Res. 2025;31:4802-4813.
    >> Share

  20. YANG Y, Nilsson MB, Yu X, Poteete A, et al
    The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells.
    Clin Cancer Res. 2025;31:4745-4762.
    >> Share

    October 2025
  21. CHONG CR, Bahcall M, Capelletti M, Kosaka T, et al
    Editor's Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
    Clin Cancer Res. 2025;31:4384.
    >> Share

    September 2025
  22. GIUDICE AM, Matlaga S, Roth SL, Gladney W, et al
    D3-GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma and small cell lung cancer.
    Clin Cancer Res. 2025 Sep 30. doi: 10.1158/1078-0432.CCR-25-0089.
    >> Share

  23. CHEN PW, Minocha M, Kong S, Jiang T, et al
    Tarlatamab exposure-efficacy and exposure-safety relationships to inform dose selection in patients with small cell lung cancer (SCLC).
    Clin Cancer Res. 2025 Sep 10. doi: 10.1158/1078-0432.CCR-25-2134.
    >> Share

    August 2025
  24. RIMNER A, Lok BH, Gelblum DY, Kotecha RR, et al
    Phase I Dose Escalation Trial Combining Olaparib and Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Aug 29. doi: 10.1158/1078-0432.CCR-24-4342.
    >> Share

  25. GAO R, Lou N, Yang S, Yang M, et al
    Multi-Omics and Single-Cell Insights Reveal a Lysophosphatidic Acid (LPA)-Mediated Resistant Mechanism to Third Generation EGFR-TKI in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Aug 25. doi: 10.1158/1078-0432.CCR-25-0993.
    >> Share

  26. CIARDULLO C, Tobalina L, Carr TH, Szekeres P, et al
    Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancer.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-2011.
    >> Share

    July 2025
  27. ZHAO L, Pang Y, Ding Y, Chen J, et al
    68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study.
    Clin Cancer Res. 2025;31:2989-3001.
    >> Share

  28. ROLFO C, O'Brate A, Menzel C, Bruns R, et al
    Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.
    Clin Cancer Res. 2025;31:2675-2684.
    >> Share

  29. JANG HJ, Patel M, Wang DY, Kang SW, et al
    Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.
    Clin Cancer Res. 2025;31:2639-2654.
    >> Share

    June 2025
  30. GAY CM, Owonikoko TK, Byers LA, Choudhury NJ, et al
    Multidimensional Analysis of B7 homolog 3 (B7-H3) RNA Expression in Small-cell Lung Cancer Molecular Subtypes.
    Clin Cancer Res. 2025 Jun 24. doi: 10.1158/1078-0432.CCR-24-3981.
    >> Share

  31. DAVAR D, Eroglu Z, Milhem M, Becerra C, et al
    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.
    Clin Cancer Res. 2025 Jun 24:OF1-OF9. doi: 10.1158/1078-0432.CCR-25-0806.
    >> Share

  32. DAVIES KD
    Finding Rearrangements in the Cell-Free DNA Haystack.
    Clin Cancer Res. 2025;31:2264-2266.
    >> Share

  33. PAWELETZ CP, Urvalek A, Ha M, Garg K, et al
    Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples.
    Clin Cancer Res. 2025;31:2406-2412.
    >> Share

  34. MACK PC, Redman MW, Tukachinsky H, Kozono DE, et al
    Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.
    Clin Cancer Res. 2025 Jun 4. doi: 10.1158/1078-0432.CCR-24-3658.
    >> Share

  35. ANDREWS HS, Zariffa N, Nishimura KK, Choi SH, et al
    ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.
    Clin Cancer Res. 2025;31:2162-2172.
    >> Share

    May 2025
  36. CHENG Y, Wang J, Yu Y, Wang Q, et al
    Phase I/II Study of Tifcemalimab, an Anti-B and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.
    Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-25-0022.
    >> Share

    April 2025
  37. ZHANG J, Jin Y, Lin H, Deng J, et al
    Amplification of extrachromosomal MYC paralogs shapes immunosuppressive tumor microenvironment in small cell lung cancer.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-3399.
    >> Share

  38. HIRSCH FR
    Antibody Drug Conjugates in Non-Small Cell Lung Cancer: Where is the Target and the Biomarker?
    Clin Cancer Res. 2025 Apr 28. doi: 10.1158/1078-0432.CCR-25-0839.
    >> Share

  39. ZHOU J, Muluneh B, Wang Z, Yao H, et al
    Leveraging Longitudinal Patient-Reported Outcomes Trajectories to Predict Survival in Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2025 Apr 24. doi: 10.1158/1078-0432.CCR-25-0292.
    >> Share

  40. PECCI F, Thummalapalli R, Alden SL, Ricciuti B, et al
    Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Apr 18:OF1-OF13. doi: 10.1158/1078-0432.CCR-24-2990.
    >> Share

  41. JENG MY, Schoenfeld AJ
    Can Longitudinal Biomarkers Guide Treatment Decisions? Time Will Tell.
    Clin Cancer Res. 2025;31:1381-1382.
    >> Share

  42. MAZZASCHI G, Marrocchio C, Moron Dalla Tor L, Leo L, et al
    Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC.
    Clin Cancer Res. 2025;31:1533-1545.
    >> Share

    March 2025
  43. KANDA S, Niho S, Kurata T, Nomura S, et al
    Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-doublet Chemotherapy for Non-small Cell Lung Cancer Harboring EGFR Mutation.
    Clin Cancer Res. 2025 Mar 31. doi: 10.1158/1078-0432.CCR-24-3532.
    >> Share

  44. KATAYAMA Y, Yamada T, Tanimura K, Kawachi H, et al
    YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
    Clin Cancer Res. 2025;31:1127-1141.
    >> Share

  45. TRONTZAS IP, He M, Wurtz A, Robbins CJ, et al
    Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Mar 6. doi: 10.1158/1078-0432.CCR-24-3347.
    >> Share

    February 2025
  46. CHENG H, Janakiram M, Borczuk A, Lin J, et al
    Editor's Note: HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Clin Cancer Res. 2025;31:788.
    >> Share

  47. WOJTALLA A, Fischer B, Kotelevets N, Mauri FA, et al
    Correction: Targeting the Phosphoinositide 3-Kinase p110-alpha Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer.
    Clin Cancer Res. 2025;31:787.
    >> Share

  48. AGGARWAL RK, Sidoli S, Wang J, Sahu S, et al
    Smoking-Associated Carcinogen-Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation.
    Clin Cancer Res. 2025;31:746-755.
    >> Share

  49. KOBOLD S
    RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
    Clin Cancer Res. 2025;31:437-438.
    >> Share

  50. JAEGER-RUCKSTUHL CA, Specht JM, Voutsinas JM, MacMillan HR, et al
    Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.
    Clin Cancer Res. 2025;31:503-514.
    >> Share

    January 2025
  51. CHIU CL, Zhang D, Zhao H, Wei Y, et al
    Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
    Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028.
    >> Share

  52. ZHANG JT, Liu SY, Gao X, Liu SM, et al
    Follow-Up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Jan 24. doi: 10.1158/1078-0432.CCR-24-2909.
    >> Share

  53. KATO R, Solanki HS, Ozakinci H, Desai B, et al
    In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C--mutant non-small cell lung cancer.
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-3714.
    >> Share

  54. CAPPUZZO F, Ricciuti B, Delmonte A, Bonanno L, et al
    MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial.
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-2077.
    >> Share

  55. SMEENK MM, van Diessen JNA, Boellaard TN, Hartemink KJ, et al
    Tremelimumab plus durvalumab prior to chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer: the Induction trial.
    Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-3476.
    >> Share

  56. ROSNER S, Connor S, Sanber K, Zahurak M, et al
    Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.
    Clin Cancer Res. 2025;31:339-351.
    >> Share

  57. REINECKE JB, Jimenez Garcia L, Gross AC, Cam M, et al
    Aberrant Activation of Wound-Healing Programs within the Metastatic Niche Facilitates Lung Colonization by Osteosarcoma Cells.
    Clin Cancer Res. 2025;31:414-429.
    >> Share

  58. DALL'OLIO FG, Zrafi W, Roelants V, Ambrosini V, et al
    Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates.
    Clin Cancer Res. 2025;31:352-364.
    >> Share

  59. NEGRAO MV, Paula AG, Molkentine D, Hover L, et al
    Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial.
    Clin Cancer Res. 2025 Jan 13. doi: 10.1158/1078-0432.CCR-24-2310.
    >> Share

  60. MEADOR CB, Digumarthy SR, Yeap BY, Hung YP, et al
    Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes.
    Clin Cancer Res. 2025;31:25-34.
    >> Share

  61. SCHULER M
    Facts and hopes in neoadjuvant immunotherapy combinations in resectable non-small-cell lung cancer.
    Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-1441.
    >> Share

    December 2024
  62. LEE S, Hamid O, Jotte R, Zakharia Y, et al
    Phase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-1478.
    >> Share

  63. AOKAGE K, Koyama S, Kumagai S, Nomura K, et al
    Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).
    Clin Cancer Res. 2024;30:5584-5592.
    >> Share

  64. SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al
    DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.
    Clin Cancer Res. 2024;30:5681-5692.
    >> Share

  65. VON ITZSTEIN MS, Burns TF, Dowell JE, Horn L, et al
    Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer.
    Clin Cancer Res. 2024 Dec 9. doi: 10.1158/1078-0432.CCR-24-1722.
    >> Share

    November 2024
  66. ALTAN M, Lopes G, Hiltermann TJN, Govindan R, et al
    Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1591.
    >> Share

  67. SOO RA, Dafni U, Han JY, Cho BC, et al
    ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
    Clin Cancer Res. 2024;30:5180-5191.
    >> Share

    October 2024
  68. STEWART CA, Diao L, Xi Y, Wang R, et al
    YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.
    Clin Cancer Res. 2024;30:4743-4754.
    >> Share

  69. VERKERK K, van der Wel TJWT, Zeverijn LJ, Geurts BS, et al
    Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer - Results from the Drug Rediscovery Protocol.
    Clin Cancer Res. 2024 Oct 1. doi: 10.1158/1078-0432.CCR-24-1925.
    >> Share

  70. LIZARDO MM, Hughes C, Huang YZ, Shyp T, et al
    Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis.
    Clin Cancer Res. 2024;30:4464-4481.
    >> Share

    September 2024
  71. MORGENSZTERN D, Ready N, Johnson ML, Dowlati A, et al
    A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.
    Clin Cancer Res. 2024 Sep 17. doi: 10.1158/1078-0432.CCR-24-1547.
    >> Share

  72. VOKES NI, Le X, Yap TA
    PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC.
    Clin Cancer Res. 2024;30:3968-3970.
    >> Share

  73. CHOI Y, Dharia NV, Jun T, Chang J, et al
    Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.
    Clin Cancer Res. 2024;30:3788-3797.
    >> Share

  74. EL ZARIF T, Meador CB, Qiu X, Seo JH, et al
    Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.
    Clin Cancer Res. 2024;30:3798-3811.
    >> Share

    August 2024
  75. KOBAN MU, Hartmann M, Amexis G, Franco P, et al
    Targeted therapies, novel antibodies, and immunotherapies in advanced non-small cell lung cancer: clinical evidence and drug approval patterns.
    Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-0741.
    >> Share

  76. OH S, Koh J, Kim TM, Kim S, et al
    Transcriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution towards small cell lung cancer.
    Clin Cancer Res. 2024 Aug 16. doi: 10.1158/1078-0432.CCR-24-0160.
    >> Share

    July 2024
  77. REINMUTH N, Juan-Vidal O, Kowalski D, Bryl M, et al
    Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.
    Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-24-0013.
    >> Share

  78. SUVILESH KN, Manjunath Y, Nussbaum YI, Gadelkarim M, et al
    Targeting AKR1B10 by drug repurposing with epalrestat overcomes chemoresistance in non-small cell lung cancer patient-derived tumor organoids.
    Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-23-3980.
    >> Share

  79. SCALERA S, Ricciuti B, Marinelli D, Mazzotta M, et al
    Transcriptional phenocopies of deleterious KEAP1 mutations correlate with survival outcomes in lung cancer treated with immunotherapy.
    Clin Cancer Res. 2024 Jul 9. doi: 10.1158/1078-0432.CCR-24-0626.
    >> Share

  80. YANG SR, Jayakumaran G, Benhamida J, Febres-Aldana CA, et al
    Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features.
    Clin Cancer Res. 2024;30:2780-2789.
    >> Share

    June 2024
  81. CHOUDHURY NJ, Lai WV, Makhnin A, Heller G, et al
    A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small cell lung cancer.
    Clin Cancer Res. 2024 Jun 28. doi: 10.1158/1078-0432.CCR-23-3383.
    >> Share

  82. BARBATO MI, Bradford D, Ren Y, Aungst SL, et al
    FDA Approval Summary: Repotrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
    Clin Cancer Res. 2024 Jun 14. doi: 10.1158/1078-0432.CCR-24-0949.
    >> Share

  83. PANG L, Huang Y, Zhuang W, Zhang Y, et al
    Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.
    Clin Cancer Res. 2024;30:2636-2646.
    >> Share

  84. DALAL B, Tada T, Patel DP, Pine SR, et al
    Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Non-smokers and Tobacco Smokers.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0637.
    >> Share

  85. ROLFO CD, Madison RW, Pasquina LW, Brown DW, et al
    Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.
    Clin Cancer Res. 2024;30:2452-2460.
    >> Share

    May 2024
  86. FUKUDA A, Okuma Y
    From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2024 May 20. doi: 10.1158/1078-0432.CCR-23-4035.
    >> Share

  87. PENG X, Zhao H, Ye L, Hou F, et al
    Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
    Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
    >> Share

  88. REKHTMAN N
    All That Is Small Is Not a Small-Cell Carcinoma: Thoracic SMARCA4-Deficient Undifferentiated Tumors Masquerading as SCLC.
    Clin Cancer Res. 2024;30:1708-1711.
    >> Share

  89. MARINIELLO A, Nasti TH, Chang DY, Hashimoto M, et al
    Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
    Clin Cancer Res. 2024;30:1833-1845.
    >> Share

    April 2024
  90. ZHOU R, Liu F, Zhang H, Wang D, et al
    Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study.
    Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-23-3600.
    >> Share

  91. ZUGAZAGOITIA J, Osma H, Baena J, Ucero AC, et al
    Facts and hopes on cancer immunotherapy for small cell lung cancer.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159.
    >> Share

  92. PERESSINI M, Garcia-Campelo R, Massuti B, Marti C, et al
    Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-24-0104.
    >> Share

  93. GRAZINI U, Markovets A, Ireland L, O'Neill D, et al
    Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2540.
    >> Share

  94. OH HJ, Bae SC, Oh IJ, Park CK, et al
    Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.
    Clin Cancer Res. 2024;30:1478-1487.
    >> Share

  95. LEE EJ, Oh SY, Lee YW, Kim JY, et al
    Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
    Clin Cancer Res. 2024;30:1582-1594.
    >> Share

  96. SINGH AK, Lewis CD, Boas CAWV, Diebolder P, et al
    Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library.
    Clin Cancer Res. 2024;30:1293-1306.
    >> Share

  97. VAIDYA P, Cohen EEW
    Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.
    Clin Cancer Res. 2024;30:1232-1239.
    >> Share

    February 2024
  98. ZHOU I, Plana D, Palmer AC
    Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
    Clin Cancer Res. 2024;30:786-792.
    >> Share

  99. KASI PM, Lee JK, Pasquina LW, Decker B, et al
    Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
    Clin Cancer Res. 2024;30:836-848.
    >> Share

  100. WEI D, Wang L, Zuo X, Maitra A, et al
    A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
    Clin Cancer Res. 2024;30:655-662.
    >> Share

  101. WANG H, Chen Y, Wang X, Huang B, et al
    Germline mutations of Holliday junction resolvase genes in multiple primary malignancies involving lung cancer lead to PARP inhibitor sensitization.
    Clin Cancer Res. 2024 Feb 13. doi: 10.1158/1078-0432.CCR-22-3300.
    >> Share

  102. VAN DE HAAR J, Mankor JM, Hummelink K, Monkhorst K, et al
    Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-4027.
    >> Share

  103. LAKHANI NJ, Rasco D, Wang H, Men L, et al
    First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
    Clin Cancer Res. 2024;30:506-521.
    >> Share

    January 2024
  104. PARRA ER, Zhang J, Duose DY, Gonzalez-Kozlova E, et al
    Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial.
    Clin Cancer Res. 2024 Jan 26. doi: 10.1158/1078-0432.CCR-23-0251.
    >> Share

  105. GUAN S, Chen X, Wei Y, Wang F, et al
    Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients.
    Clin Cancer Res. 2024 Jan 23. doi: 10.1158/1078-0432.CCR-23-2357.
    >> Share

  106. KESARI S, Wagle N, Carrillo JA, Sharma A, et al
    Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
    Clin Cancer Res. 2024;30:323-333.
    >> Share

  107. NG J, Cai L, Girard L, Prall OWJ, et al
    Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
    Clin Cancer Res. 2024 Jan 5:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-2360.
    >> Share

  108. NAKAMICHI S, Kubota K, Misumi T, Kondo T, et al
    Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study).
    Clin Cancer Res. 2024 Jan 2. doi: 10.1158/1078-0432.CCR-23-2568.
    >> Share

    December 2023
  109. LOPEZ DE RODAS M, Wang Y, Peng G, Gu J, et al
    Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer (NSCLC).
    Clin Cancer Res. 2023 Dec 21. doi: 10.1158/1078-0432.CCR-23-2457.
    >> Share

  110. PASSIGLIA F, Righi L, Bironzo P, Listi A, et al
    Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial.
    Clin Cancer Res. 2023 Dec 18. doi: 10.1158/1078-0432.CCR-23-2431.
    >> Share

  111. BOUMELHA J, Molina-Arcas M, Downward J
    Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
    Clin Cancer Res. 2023;29:5012-5020.
    >> Share

  112. HUMMELINK K, Tissier R, Bosch LJW, Krijgsman O, et al
    A dysfunctional T cell gene signature for predicting non-response to PD-1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-1061.
    >> Share

  113. ROLFO C, Russo A
    In search of lost biomarker for immunotherapy in small-cell lung cancer.
    Clin Cancer Res. 2023 Dec 12. doi: 10.1158/1078-0432.CCR-23-3087.
    >> Share

  114. BESSEDE A, Peyraud F, Besse B, Cousin S, et al
    TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-2566.
    >> Share

  115. VOKES NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, et al
    ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
    Clin Cancer Res. 2023;29:4958-4972.
    >> Share

    November 2023
  116. MURRAY JC, Sivapalan L, Hummelink K, Balan A, et al
    Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1469.
    >> Share

    October 2023
  117. HERBST RS, Blanke CD, Sigal EV
    Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships.
    Clin Cancer Res. 2023 Oct 30. doi: 10.1158/1078-0432.CCR-23-2690.
    >> Share

  118. ZHOU X, Zhou L, Yao Z, Huang M, et al
    Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.
    Clin Cancer Res. 2023;29:4098-4108.
    >> Share

  119. PAZ-ARES L, Garassino MC, Chen Y, Reinmuth N, et al
    Durvalumab +/- tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1689.
    >> Share

    September 2023
  120. BESSEDE A, Peyraud F, Le Moulec S, Cousin S, et al
    Upregulation of Indoleamine 2,3-dioxygenase 1 in tumor cells and tertiary lymphoid structures is a hallmark of inflamed non-small cell lung cancer.
    Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-1928.
    >> Share

  121. DIMOU A
    Time to Think About Human Leukocyte Antigen-Based Diagnostics in Lung Cancer?
    Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-2152.
    >> Share

  122. SOLTA A, Boettiger K, Kovacs I, Lang C, et al
    Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair.
    Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-1795.
    >> Share

  123. CANTOR DJ, Aggarwal C
    Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
    Clin Cancer Res. 2023;29:3563-3565.
    >> Share

  124. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:3573-3578.
    >> Share

  125. ABEL ML, Takahashi N, Peer C, Redon CE, et al
    Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
    Clin Cancer Res. 2023;29:3603-3611.
    >> Share

  126. PELLINI B, Madison RW, Childress M, Miller ST, et al
    Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023 Sep 13. doi: 10.1158/1078-0432.CCR-23-1578.
    >> Share

  127. GRAY JE, Ahn MJ, Oxnard GR, Shepherd FA, et al
    Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
    Clin Cancer Res. 2023;29:3340-3351.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016